14.36

0.28% -0.04

After Hours: 14.36

Anika Therapeutics Inc (ANIK)

Overview News Price History Option Chain Financials Discussions Forecast

Anika Therapeutics Inc stock is traded at $14.36, with a volume of 136.55K. It is down -0.28% in the last 24 hours and up +34.58% over the past month. Anika Therapeutics Inc is an orthopedic medicines company. It is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies. The company focuses on orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies. Geographically, it derives a majority of its revenue from the United States and also has its presence in Europe and Other countries.

Previous Close:

$14.40

Open:

$14.27

24h Volume:

136.55K

Relative Volume:

0.88

Market Cap:

$207.09M

Revenue:

$166.88M

Net Income/Loss:

$-74.18M

P/E Ratio:

-2.8323

EPS:

-5.07

Net Cash Flow:

$1.14M

1W Performance:

+31.26%

1M Performance:

+34.58%

6M Performance:

+57.98%

1Y Performance:

-14.83%

1-Day Range:

$14.18

$14.63

1-Week Range:

$11.60

$14.67

52-Week Range:

$7.8701

$17.35

Anika Therapeutics Inc Stock (ANIK) Company Profile

Name

Anika Therapeutics Inc

Sector

Healthcare (1106)

Industry

Drug Manufacturers - Specialty & Generic (82)

Phone

(781) 457-9000

Address

32 WIGGINS AVENUE, BEDFORD, MA

Employee

288

Twitter

Next Earnings Date

2025-03-12

Latest SEC Filings

ANIK's Discussions on Twitter

Compare ANIK vs TAK, ZTS, HLN, TEVA, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ANIK Anika Therapeutics Inc	14.36	207.67M	166.88M	-74.18M	1.14M	-5.07
TAK Takeda Pharmaceutical Co Adr	18.22	57.12B	29.85B	776.90M	4.35B	0.2408
ZTS Zoetis Inc	125.96	53.16B	9.47B	2.67B	2.28B	6.0218
HLN Haleon Plc Adr	10.47	47.25B	14.54B	2.22B	2.58B	0.4879
TEVA Teva Pharmaceutical Industries Ltd Adr	32.91	37.59B	17.41B	1.43B	1.00B	1.2182
UTHR United Therapeutics Corp	490.21	21.85B	3.13B	1.27B	1.12B	26.39

Anika Therapeutics Inc Stock (ANIK) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-17-25	Initiated	B. Riley Securities	Buy
Nov-01-24	Reiterated	Barrington Research	Outperform
Aug-14-23	Upgrade	Barrington Research	Mkt Perform → Outperform
Mar-07-23	Downgrade	Barrington Research	Outperform → Mkt Perform
Nov-09-22	Upgrade	Barrington Research	Mkt Perform → Outperform
Oct-14-22	Resumed	Stephens	Equal-Weight
Mar-09-22	Downgrade	Barrington Research	Outperform → Mkt Perform
Mar-09-22	Downgrade	Stephens	Overweight → Equal-Weight
Nov-16-21	Initiated	Stephens	Overweight
Jul-16-21	Initiated	UBS	Neutral
Dec-16-20	Upgrade	Barrington Research	Mkt Perform → Outperform
May-08-20	Downgrade	Barrington Research	Outperform → Mkt Perform
Jan-21-20	Upgrade	Sidoti	Neutral → Buy
Jan-10-20	Upgrade	First Analysis Sec	Outperform → Strong Buy
Nov-05-19	Initiated	BWS Financial	Sell
Sep-24-19	Reiterated	Barrington Research	Outperform
Sep-23-19	Downgrade	First Analysis Sec	Strong Buy → Outperform
Jul-25-19	Upgrade	First Analysis Sec	Neutral → Strong Buy
Feb-22-19	Downgrade	First Analysis Sec	Outperform → Neutral
Feb-22-19	Downgrade	Sidoti	Buy → Neutral
Jul-27-18	Upgrade	Barrington Research	Mkt Perform → Outperform
Jun-20-18	Downgrade	Barrington Research	Outperform → Mkt Perform
Jun-20-18	Downgrade	First Analysis Sec	Overweight → Equal-Weight
May-04-18	Upgrade	Barrington Research	Mkt Perform → Outperform
Feb-23-18	Downgrade	Barrington Research	Outperform → Mkt Perform
Jan-24-18	Upgrade	First Analysis Sec	Equal-Weight → Overweight
Oct-27-17	Reiterated	Barrington Research	Outperform
May-09-16	Upgrade	Singular Research	BUY - Long-Term → Buy
Apr-27-16	Downgrade	Northland Capital	Outperform → Market Perform
Feb-26-16	Reiterated	Barrington Research	Outperform

View All

Anika Therapeutics Inc Stock (ANIK) Latest News

08:55 AM

Top 2 Health Care Stocks That May Crash This QuarterArcellx (NASDAQ:ACLX), Anika Therapeutics (NASDAQ:ANIK) - Benzinga

08:55 AM

03:36 AM

Anika Therapeutics Is Cheap, But FDA Decisions And OEM Pricing Still Rule - Finimize

03:36 AM

Mar 03, 2026

Anika Therapeutics debuts Integrity and highlights portfolio at AAOS, Anika Therapeutics asserts - Traders Union

Mar 03, 2026

Anika Therapeutics 2025 10-K: Revenue $112.8M, Diluted Loss per Share $(0.70) - TradingView

Mar 03, 2026

Anika Therapeutics Touts $3B TAM, Cingal & Hyalofast Growth Plans at Canaccord MSK Conference - Yahoo Finance

Mar 03, 2026

Mar 02, 2026